Capital Performance Advisors LLP Purchases Shares of 1,723 Gilead Sciences, Inc. (NASDAQ:GILD)

Capital Performance Advisors LLP acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,723 shares of the biopharmaceutical company’s stock, valued at approximately $144,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in GILD. CarsonAllaria Wealth Management Ltd. lifted its holdings in Gilead Sciences by 198.3% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 238 shares during the period. nVerses Capital LLC acquired a new position in shares of Gilead Sciences in the 3rd quarter valued at about $25,000. Valued Wealth Advisors LLC boosted its position in shares of Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 161 shares in the last quarter. Cedar Wealth Management LLC grew its stake in Gilead Sciences by 51.6% during the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 160 shares during the period. Finally, Strategic Investment Solutions Inc. IL acquired a new stake in Gilead Sciences during the second quarter worth approximately $33,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Johanna Mercier sold 5,490 shares of the stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the transaction, the insider now owns 114,979 shares in the company, valued at approximately $8,506,146.42. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Gilead Sciences news, insider Johanna Mercier sold 5,490 shares of the business’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total value of $406,150.20. Following the transaction, the insider now directly owns 114,979 shares in the company, valued at $8,506,146.42. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Merdad Parsey sold 25,590 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the sale, the insider now owns 99,599 shares of the company’s stock, valued at approximately $9,113,308.50. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 62,437 shares of company stock valued at $5,374,825 in the last ninety days. 0.29% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

GILD has been the topic of a number of research analyst reports. Robert W. Baird increased their price target on Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a report on Thursday. Leerink Partnrs upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 21st. Cantor Fitzgerald upped their price objective on shares of Gilead Sciences from $70.00 to $80.00 and gave the company a “neutral” rating in a report on Thursday. Evercore ISI upgraded Gilead Sciences to a “strong-buy” rating in a research note on Friday, August 9th. Finally, The Goldman Sachs Group boosted their target price on Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a research report on Thursday. Twelve analysts have rated the stock with a hold rating, ten have issued a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $90.71.

Gilead Sciences Stock Down 1.4 %

GILD opened at $96.57 on Friday. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.32. The firm has a market capitalization of $120.22 billion, a P/E ratio of 117.76, a PEG ratio of 3.13 and a beta of 0.17. The company’s 50-day moving average is $85.30 and its 200 day moving average is $75.03. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.14 and a quick ratio of 0.95.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The company’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter last year, the firm earned $2.29 EPS. Research analysts expect that Gilead Sciences, Inc. will post 3.75 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be paid a $0.77 dividend. The ex-dividend date is Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.19%. Gilead Sciences’s dividend payout ratio (DPR) is presently 375.61%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.